Exelixis Hands Merck PI3K-Delta Program in $251M Deal
True to its word, Exelixis Inc. started to prune its pipeline this week, handing Merck & Co. Inc. an exclusive worldwide license to its phosphoinositide-3 kinase (PI3K)-delta research and development program, including XL499 – the company's most advanced preclinical PI3K-delta inhibitor – and related compounds.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter